10 Best Heal Care Stocks To Buy For 2014

Here are today's top news headlines from�Fool.com. Check back throughout the day as this list is updated, and follow us on Twitter at�TMFBreaking.

Campbell Soup to Acquire Danish Cookie Maker

Regulators Cut Back on Duke's Rate Request

Elan Shareholder's Vote Nixes Royalty Pharma Deal

PetSmart Declares Quarterly Dividend

easyJet Confirms Purchase of up to 235 New Planes

Yahoo! Discloses Government Data Requests

Natural Resource Partners to Expand in the Bakken

SodaStream Partners With Whirlpool's KitchenAid

Russia Lands $572.2 Million Pentagon Contract to Boost Afghan Air Forces

EarthLink to Acquire CenterBeam for $22 Million

Hewlett-Packard Creates New Executive Role to Enhance Growth

Starbucks to Post Calorie Information in Stores

Amazon Birthday Gift Cards Go Social

Bank of America Sets Preferred Dividend

Baytex Energy Sets June Monthly Payment

Dynamic Materials Keeps Dividend Steady

Top Beverage Stocks To Buy For 2015: Givaudan SA (GIVN)

Givaudan SA is a Switzerland-based holding company engaged in the fragrance and flavor industry. The Company has two business divisions: Fragrances and Flavors. The Fragrances business segment comprises the manufacture and sale of fragrances into three global business units: Fine Fragrances, comprising signature fragrances and line extensions, Consumer Products, comprising fabric and personal care, hair and skin care, household and air care, as well as oral care, and Fragrance Ingredients. The Flavors business division comprises the manufacture and sale of flavors into four business units: Beverages, comprising flavors for soft drinks, fruit juices and instant beverages; Dairy, comprising ice cream, yoghurt, desserts and yellow fats; Savory, covering soups and sauces, among others; and Confectionery. The Company is also engaged in research and development activities, which comprises the development of a palette of perfumery raw materials, both synthetic and natural. Advisors' Opinion:

• [By Celeste Perri]

  Nestle SA (NESN) is selling Givaudan (GIVN) SA shares worth $1.27 billion at yesterday�� closing price to institutional investors, winding down its stake in the world�� largest flavorings maker.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Given Imaging (Nasdaq: GIVN  ) , whose recent revenue and earnings are plotted below.

• [By Inyoung Hwang]

  Berkeley Group Holdings Plc (BKG) surged 8.3 percent after saying first-half profit rose 22 percent. London Stock Exchange Group Plc (LSE) climbed 2.4 percent after Bank of America Corp.�� Merrill Lynch unit recommended buying the stock. Givaudan SA (GIVN) lost 1.3 percent after Nestle SA said it will sell $1.27 billion of shares in the world�� largest flavorings maker.

10 Best Heal Care Stocks To Buy For 2014: On Assignment Inc.(ASGN)

On Assignment, Inc., a diversified professional staffing firm, provides flexible and permanent staffing solutions in the United States, Europe, Canada, Australia, and New Zealand. The company?s Life Sciences segment provides contract and permanent life science professionals to clients in the biotechnology, pharmaceutical, food and beverage, personal care, chemical, medical device, automotive, municipal, education, and environmental industries. Its contract professionals include chemists, clinical research associates, clinical lab assistants, engineers, biologists, biochemists, microbiologists, molecular biologists, biostatisticians, drug safety specialists, SAS programmers, medical writers, food scientists, regulatory affairs specialists, lab assistants, and other skilled scientific professionals. The company?s Healthcare segment offers locally-based and traveling contract professionals that include nurses, specialty nurses, respiratory therapists, surgical technicians, imaging technicians, X-ray technicians, medical technologists, medical assistants, pharmacists, pharmacy technicians, respiratory therapists, phlebotomists, coders, billers, claims processors, and collections staff, as well as dental professionals. This segment serves hospitals, integrated delivery systems, imaging centers, clinics, physician offices, reference laboratories, universities, managed care organizations, and third-party administrators. Its Physician segment provides short and long-term locum tenens services, and full-service physician search and consulting services. The company?s IT and Engineering segment offers high-end contract and direct placement services of information technology and engineering professionals with expertise in specialized information technology; software and hardware engineering; and mechanical, electrical, validation, and telecommunications engineering fields. On Assignment, Inc. was founded in 1985 and is headquartered in Calabasas, Cali fornia.

Advisors' Opinion:

• [By Garrett Cook]

  On Assignment (NYSE: ASGN) shares tumbled 22.61 percent to $27.01 after the company reported Q2 earnings of $0.56 per share on revenue of $468.60 million. Baird downgraded the stock from Outperform to Neutral.

• [By Monica Gerson]

  © 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Most Popular Are Massive Xbox One 'Titanfall' Sales To Blame For Xbox 360 Game Delay? Warren Buffett's Conflicting Bitcoin Views Marijuana Economy Has Plenty Of Room To Grow Fox On Stocks' 17-Year-Old Rachel Fox Teaches A New Generation How To Trade Mid-Morning Market Update: Markets Edge Higher; FedEx Profit Misses Estimates Five Star Stock Watch: Herbalife Related Articles (ASBC + ASGN)
• [By Brian Pacampara]

  What: Shares of professional staffing firm On Assignment (NYSE: ASGN  ) popped 11% today after its quarterly results and guidance topped Wall Street expectations.

10 Best Heal Care Stocks To Buy For 2014: Embraer-Empresa Brasileira de Aeronautica(ERJ)

Embraer S.A. engages in the development, production, and sale of jet and turboprop aircraft for civil and defense aviation markets. It also offers aircrafts for agricultural use; structural components, mechanical and hydraulic systems, and technical activities related to the production and maintenance of aerospace material. The company?s Commercial Aviation segment designs, develops, and manufactures various commercial aircraft for regional, low-cost, and mainline airlines primarily in Europe, the Middle East, Africa, Asia, and the Americas. Its Defense and Security segment provides a range of integrated solutions for the defense and security market, including training/light attack aircraft, aerial surveillance platforms, military transport aircraft, and government transport aircraft; command, control, communications, computer, intelligence, surveillance, and reconnaissance systems; and maintenance and material solutions. The company?s Executive Aviation segment develops a line of executive jets for fractional ownership companies, charter companies and air-taxi companies, and high-net-worth individuals. Its Aviation Services segment offers after-sales customer support services for the fleets of its commercial, executive, and defense customers. This segment also provides spare parts, maintenance and repair, training, and other product support services. The company?s Other segment involves in selling and leasing used aircraft; and offers structural parts, and mechanical and hydraulic systems for the production of helicopters. This segment also manufactures landing gear, and general aviation propeller aircraft, such as executive planes and crop dusters. It has a strategic alliance with European Aerospace and Defense Group. The company was formerly known as Embraer - Empresa Brasileira de Aeron Advisors' Opinion:

• [By Adam Levine-Weinberg]

  Legacy carrier United Continental (NYSE: UAL  ) was busy at last week's Paris Air Show. The annual air shows are a forum for aircraft manufacturers like Boeing (NYSE: BA  ) , Airbus, and Embraer (NYSE: ERJ  ) to show off their latest airplanes and market them to major airlines and leasing companies. Many aircraft purchase deals are typically signed and announced at the air shows each year. This year, United signed two new deals, giving business to both Boeing and Airbus.

• [By Rex Moore]

  Brazilian jet-maker Embraer (NYSE: ERJ  ) has long been a high flyer in the commercial aviation sector. Recently, however, the company has been growing its executive aviation and defense segments.

• [By Ben Levisohn]

  Shares of Boeing have dropped 8.9% this year, after gaining 84% in 2013. Airbus (EADSY), by comparison, has fallen 9.2% in 2014, after gaining 94% last year, while Embraer (ERJ) has gained 6.4% this year after rising 14% in 2013.

10 Best Heal Care Stocks To Buy For 2014: Uralkaliy OAO (URALL.PK)

Uralkaliy OAO (Uralkali OJSC) is a Russia-based company, which is engaged in the chemical industry. The Company specializes in the production of potash fertilizers. Its product portfolio comprises pink muriate of potash (PMOP), white muriate of potash (WMOP) and granular (GMOP). The Company is active through representative offices, located in Moscow and Beijing, as well as numerous subsidiaries, located countrywide and in Panama, Belarus, Singapore, Brazil and others. Uralkaliy OAO operates on the potassium and magnesium deposits located in Berezniki, Perm and Saint Petersburg. Its production assets include seven plants and five mines. Uralkaliy OAO sells its products domestically, as well as abroad in over 40 countries, including the United States, China, Brazil, India and South-East Asia, among others. Advisors' Opinion:

• [By Chris Damas]

  This morning Russian potash giant OJSC Uralkali (URALL.PK) presented first half 2013 financial and operating results and more importantly, much anticipated comments on the strategy of the company and the state of the international potash industry, the latter blind-sided by the leading potash company's split with marketing partner JSC Belaruskali of Belarus.

10 Best Heal Care Stocks To Buy For 2014: Walter Bau AG (WTB)

Walter Bau AG is an international construction group based in Augsburg, southern Germany. The Company's core construction-related services are planning, financing, project development and facilities management. It is active in the fields of turnkey construction, civil engineering, international construction and transportation infrastructure. Its subsidiary, DYWIDAG-Systems International markets the Company's products and systems worldwide, particularly in the field of post-tensioning and geotechnics, as well as special civil engineering processes. Walter Bau also provides operation and financing solutions, as well as developing commercial and residential real estate projects. Facilities Management is offered by DYWIDAG Service GmbH. Its Logistics Competence Center in Augsburg bundles the Company's Germany-wide activities as a general contractor in the planning, construction and support of distribution centers. The Company commenced insolvency proceedings in April 2005. Advisors' Opinion:

• [By Namitha Jagadeesh]

  BHP Billiton Ltd. (BHP) and Rio Tinto Group, the world�� biggest mining companies, fell at least 3 percent. Whitbread Plc (WTB) dropped 2.8 percent after UBS AG downgraded the owner of the Costa Coffee chain. British Land Co., the U.K.�� second-largest real estate investment trust, advanced 1.2 percent after saying it bought commercial property in London for 470 million pounds ($707 million).

• [By Sofia Horta e Costa]

  Whitbread Plc (WTB) added 4.1 percent to 3,114 pence, its largest advance since September 2012. Oriel Securities Ltd. raised its rating on the shares to buy from hold, citing improvement in the U.K. hotel market.

10 Best Heal Care Stocks To Buy For 2014: AEterna Zentaris Inc.(AEZS)

Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company?s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.

Advisors' Opinion:

• [By Sean Williams]

  What's coming down the pipeline
  As we saw with the current treatment options, the endometrial cancer pipeline isn't filled with a lot of choices, but they are at least more encouraging than the standard care treatments we've seen over the past three decades.

  Avastin: Surprise: It's Roche's (NASDAQOTH: RHHBY  ) wonder drug yet again! Roche's Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don't be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results.� AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS  ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthetic peptide carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.

  Your best investment
  With very few investable options to choose from, since many of these treatments are off patent as they're decades old, I'm going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons.

• [By Roberto Pedone]

  Aeterna Zentaris (AEZS), a specialty biopharmaceutical company, is focused on developing and commercializing novel treatments in oncology and endocrinology. This stock closed up 5% to $1.25 in Thursday's trading session.

  Thursday's Range: $1.19-$1.26
  52-Week Range: $0.99-$1.75
  Thursday's Volume: 1.32 million
  Three-Month Average Volume: 646,050

  From a technical perspective, AEZS ripped sharply higher here right above its 50-day moving average of $1.17 and back above its 200-day moving average of $1.22 with strong upside volume flows. This sharp spike higher on Thursday also pushed shares of AEZS into breakout territory, since the stock took out some more near-term overhead resistance at $1.23. This move is starting to push shares of AEZS within range of triggering another big breakout trade. That trade will hit if AEZS manages to take out some key overhead resistance levels at $1.28 to $1.35 with high volume.

  Traders should now look for long-biased trades in AEZS as long as it's trending above its 200-day at $1.22 or above Thursday's intraday low of $1.19 and then once it sustains a move or close above those breakout levels with volume that hits near or above 646,050 shares. If that breakout begins soon, then AEZS will set up to re-test or possibly take out its next major overhead resistance levels at $1.52 to $1.62.

• [By Eric Volkman]

  Aeterna Zentaris (NASDAQ: AEZS  ) has made a significant change in its executive suite and boardroom. David Dodd is now the company's chief executive and a member of its board of directors. He succeeds Juergen Engel. The firm did not provide the reasons for the succession.

• [By Sean Williams]

  High-risk, high-reward suggestions
  There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.

  Exelixis (NASDAQ: EXEL  ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN  ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to

10 Best Heal Care Stocks To Buy For 2014: Synovus Financial Corp.(SNV)

Synovus Financial Corp., a diversified financial services and bank holding company, provides commercial and retail banking, financial management, insurance, and mortgage services in Georgia, Alabama, South Carolina, Florida, and Tennessee. Its retail banking services include accepting customary types of demand and savings deposits; mortgage, installment, and other retail loans; investment and brokerage services; safe deposit services; automated banking services; automated fund transfers; Internet based banking services; and bank credit card services, including mastercard and visa services. The company?s commercial banking services comprise cash management and asset management services, capital markets services, and institutional trust services, as well as commercial, financial, and real estate loans. It also provides various other financial services, which include the portfolio management for fixed-income securities, investment banking, the execution of securities transac tions as a broker/dealer, and the provision of individual investment advice on equity and other securities; trust services; mortgage services; and financial planning services. Synovus Financial Corp. was founded in 1888 and is headquartered in Columbus, Georgia.

Advisors' Opinion:

• [By Robert Eberhard]

  Synovus Financial (NYSE: SNV  ) throws its hat into the earnings ring early Tuesday, and investors are facing a big question: Will CEO Kessel D. Stelling and crew deliver good news? Or should investors be wary of less than impressive results?

• [By Rich Duprey]

  Southeastern regional bank�Synovus Financial (NYSE: SNV  ) �announced this morning�its second-quarter dividend of $0.01 per share, the same rate it's paid since 2009.

• [By Selena Maranjian]

  Caxton Associates reduced its stake in lots of companies, including Georgia-based Synovus Financial (NYSE: SNV  ) . Synovus has been posting strong return-on-equity (ROE) numbers. In May, it acquired $54 million in deposits from the failed Sunrise Bank. Bears worry about the bank's significant residential real estate business and the current low interest rate environment. It has also been working to pay off its TARP obligations.

• [By John Maxfield]

  Given that you clicked on this article, it seems safe to assume you either own stock in Synovus Financial (NYSE: SNV  ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers that investors need to know about Synovus stock before deciding whether to buy, sell, or hold it.